Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

GLUCO-SCAN

financed

Closed

Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to...

Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging... see more

30/11/2028

MEDIZINISCHE UNIVE...

2M€

Project Budget: 2M€

Project leader

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2023-12-01

ERC-2022-COG: ERC CONSOLIDATOR GRANTS Scope:Objectives

I+D

Cerrada

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MEDIZINISCHE UNIVERSITAET WI...

Leader

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 59 months Date Start: 2023-12-01
End date: 2028-11-30

Project leader

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET). Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations: PET involves harmful ionizing radiation, is expensive, not widely available, and cannot differentiate between cancer-specific and normal cellular glucose uptake. These limitations prohibit an even more widespread use of PET, e.g. for screening. We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI) that will overcome these limitations.Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g., targeting Glc metabolism in cancer. After ingestion, this labeled Glc is metabolized in cells and the label is transferred to all metabolic products, which can be tracked by DMI.Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:(i) Is DMI a viable alternative for whole-body cancer assessment?(ii) How is DMI positioned compared to Glc-sensitive PET?(iii) Can DMI be performed on widely available MRI systems and simultaneous with standard MRI?GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers